Skip to main content
SpringerLink
Log in

Current Topics

  • Chapter
  • First Online:
Current Schizophrenia

  • 2243 Accesses

Abstract

Over the last two decades, the treatment of psychosis has advanced substantially; yet, despite all progress, the immense individual and societal burden associated with psychosis, particularly due to schizophrenia, has largely stayed the same. Retrospective studies on the often years-long prodrome of psychotic disorders have shown that the vast majority of patients develop, among others, cognitive, perceptive, negative, and affective symptoms as well as precursors of positive symptoms and a significant loss of functioning even during the early phase of illness. Further, a long duration of untreated psychosis (DUP; time between the onset of the first frank psychotic symptom and the first adequate treatment) and a long duration of untreated illness (time between the onset of the first prodromal symptom and the first adequate treatment), have both been linked to a more negative outcome. For these reasons, an indicated prevention strategy of psychotic disorders and their negative consequences before they set in is regarded as the most promising approach to the management of these disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. McGlashan T, Walsh B, Woods S. The Psychosis-Risk Syndrome Handbook for Diagnosis and Follow-Up. New York, NY: Oxford University Press; 2010.

    Google Scholar 

  2. Schultze-Lutter F, Michel C, Ruhrmann S, Klosterkotter J, Schimmelmann BG. Prediction and early detection of first-episode psychosis. In: Ritsner M, ed. Textbook of Schizophrenia Spectrum Disorders, Volume II. Dordrecht, the Netherlands: Springer Science + Business Media; 2011:207-268.

    Google Scholar 

  3. The American Psychiatric Association DSM-5 development: proposed draft revisions to DSM disorders and criteria. www.dsm5.org/ProposedRevision/Pages/Default.aspx. Accessed April 2, 2012.

  4. Carpenter WT Jr. Criticism of the DSM-V risk syndrome: a rebuttal. Cogn Neuropsychiatry. 2011;16:101-106.

    Google Scholar 

  5. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159:863-865.

    Google Scholar 

  6. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res. 2003;60:21-32.

    Google Scholar 

  7. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004; 67:131-142.

    Google Scholar 

  8. Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull. 2006;32:166-178.

    Google Scholar 

  9. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65:28-37.

    Google Scholar 

  10. Ruhrmann S, Schultze-Lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010;67:241-251.

    Google Scholar 

  11. Simon AE, Umbricht D. High remission rates from an initial ultra-high risk state for psychosis. Schizophr Res. 2010;116:168-172.

    Google Scholar 

  12. Addington J, Cornblatt BA, Cadenhead KS, et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011;168:800-805.

    Google Scholar 

  13. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39:964-971.

    Google Scholar 

  14. Schultze-Lutter F, Klosterkotter J Picker H, Steinmeyer EM, Ruhrmann S. Predicting first-episode psychosis by basic symptom criteria. Clin Neuropsych. 2007;4:11-22.

    Google Scholar 

  15. Schultze-Lutter F, Ruhrmann S, Klosterkotter J. Can schizophrenia be predicted phenomenologically? In: Johannesen JO, Martindale BV, Cullberg J, eds. Evolving Psychosis: Different Stages, Different Treatments. Hove, UK: Routledge; 2006:104-123.

    Google Scholar 

  16. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001,58:158-164.

    Google Scholar 

  17. Klosterkotter J, Ruhrmann S, Schultze-Lutter F, et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry. 2005;4:161-167.

    Google Scholar 

  18. Klosterkotter J, Schultze-Lutter F, Bechdolf A, Ruhrmann S. Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry. 2011;10:165-174.

    Google Scholar 

  19. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: a meta-analysis of evidence. Arch Gen Psychiatry. In press.

    Google Scholar 

  20. Koch E, Schultze-Lutter F, Schimmelmann BG, Resch F. On the importance and detection of prodromal symptoms from the perspective of child and adolescent psychiatry. Clin Neuropsych. 2010;7:38-48.

    Google Scholar 

  21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Text Revision). 4th edn. Washington, DC: American Psychiatric Press; 1994.

    Google Scholar 

  22. Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res. 2010;123:30-36.

    Google Scholar 

  23. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiat. 2006;163:790-799.

    Google Scholar 

  24. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiat. 2002;59:921-928.

    Google Scholar 

  25. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Brit J Psychiat. 2004;185:291-297.

    Google Scholar 

  26. Bechdolf A, Wagner M, Ruhrmann S, et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry. 2012;200:22-29.

    Google Scholar 

  27. Ruhrmann S, Bechdolf A, Kuhn KU, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry. 2007;191(suppl 51):s88-s95.

    Google Scholar 

  28. Amminger GP, Schafer MR, Klier CM, et al. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Mol Psychiatry. 2011. [Epub ahead of print].

    Google Scholar 

  29. International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry Suppl. 2005;48:s120-s124.

    Google Scholar 

  30. McGorry P, Killackey E, Elkins K, Lambert M, Lambert T. Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia (2003). Australasian Psych. 2003;11:136-147.

    Google Scholar 

  31. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res. 2009;113:189-199.

    Google Scholar 

  32. Moritz S, Woodward TS. Metacognitive training in schizophrenia: from basic research to knowledge translation and intervention. Curr Opin Psychiatry. 2007;20:619-625.

    Google Scholar 

  33. Caldwell C, Gottesman I. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull. 1990;16:571-589.

    Google Scholar 

  34. Limosin F, Loze JY, Philippe A, Casadebaig F, Rouillon F. Ten-year prospective follow-up study of the mortality by suicide in schizophrenic patients. Schizophrenia Research. 2007;94:23-28.

    Google Scholar 

  35. Stephens J, Richard P, McHugh PR. Suicide in patients hospitalized for schizophrenia: 1913- 1940. J Nerv Ment Dis. 1999;187:10-14.

    Google Scholar 

  36. Tanney BL. Psychiatric diagnoses and suicidal acts. In: Maris RW, Berman AL, Silverman MM, eds. Comprehensive Textbook of Suicidology. New York, NY: Guilford Press; 2000: 311-341.

    Google Scholar 

  37. Harkavy-Friedman JM, Nelson EA. Assessment and intervention for the suicidal patient with schizophrenia. Psychiatr Q. 1997;68:361-375.

    Google Scholar 

  38. Kallert TW, Leisse M, Winiecki P. Suicidality of chronic schizophrenic patients in long-term community care. Crisis. 2004;25:54-64.

    Google Scholar 

  39. Fenton WS. Depression, suicide, and suicide prevention in schizophrenia. Suicide Life Threat Behav. 2000;30:34-49.

    Google Scholar 

  40. Robinson J, Cotton S, Conus P, Schimmelmann BG, McGorry P, Lambert M. Prevalence and predictors of suicide attempt in an incidence cohort of 661 young people with first-episode psychosis. Aust N Z J Psychiatry. 2009;43:149-157.

    Google Scholar 

  41. Power PJ, Bell RJ, Mills R, et al. Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Aust N Z J Psychiatry. 2003;37:414-420.

    Google Scholar 

  42. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46.

    Google Scholar 

  43. Lambert M, Conus P, Cotton S, Robinson J, McGorry PD, Schimmelmann BG. Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis. J Clin Psychopharmacol. 2010;30:565-572.

    Google Scholar 

  44. Conus P, Lambert M, Cotton S, Bonsack C, McGorry PD, Schimmelmann BG. Rate and predictors of service disengagement in an epidemiological first-episode psychosis cohort. Schizophr Res. 2010;118:256-263.

    Google Scholar 

  45. Schimmelmann BG, Conus P, Schacht M, McGorry P, Lambert M. Predictors of service disengagement in first-admitted adolescents with psychosis. J Am Acad Child Adolesc Psychiatry. 2006;45:990-999.

    Google Scholar 

  46. Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32:724-742.

    Google Scholar 

  47. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892-909.

    Google Scholar 

  48. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010; 71(suppl 2):20-26.

    Google Scholar 

  49. President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. bioethics.georgetown.edu/pcbe/reports/past_commissions/ making_health_care_decisions.pdf. Accessed April 2, 2012.

    Google Scholar 

  50. Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters. Patient Educ Couns. 2006;60:301-312.

    Google Scholar 

  51. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011;(6):CD002831.

    Google Scholar 

  52. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry. 1995;152:453-455.

    Google Scholar 

  53. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986;143:993-997.

    Google Scholar 

  54. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992;149:1189-1194.

    Google Scholar 

  55. Yarnold PR, Levinson DF, Singh H, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull. 1990;16:31-56.

    Google Scholar 

  56. Barnett JH, Werners U, Secher SM, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry. 2007;190:515-520.

    Google Scholar 

  57. Mauri MC, Volonteri LS, De Gaspari IF, Colasanti A, Brambilla MA, Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health. 2006;2:4.

    Google Scholar 

  58. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011;342:d738.

    Google Scholar 

  59. Meister K, Burlon M, Rietschel L, Gouzoulis-Mayfrank E, Bock T, Lambert M. [Dual diagnosis psychosis and substance use disorders in adolescents – part 1]. Fortschr Neurol Psychiatr. 2010;78:81-89.

    Google Scholar 

  60. Meister K, Rietschel L, Burlon M, Gouzoulis-Mayfrank E, Bock T, Lambert M. [Dual diagnosis psychosis and substance use disorders in adolescents – part 2]. Fortschr Neurol Psychiatr. 2010;78:90-100.

    Google Scholar 

  61. Morgan C, Fisher H. Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma – a critical review. Schizophr Bull. 2007;33:3-10.

    Google Scholar 

  62. Janssen I, Krabbendam L, Bak M, et al. Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatr Scand. 2004;109:38-45.

    Google Scholar 

  63. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627.

    Google Scholar 

  64. Gearon JS, Kaltman SI, Brown C, Bellack AS. Traumatic life events and PTSD among women with substance use disorders and schizophrenia. Psychiatr Serv. 2003;54:523-528.

    Google Scholar 

  65. Fan X, Henderson DC, Nguyen DD, et al. Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. Psychiatry Res. 2008;159:140-146.

    Google Scholar 

  66. Quarantini LC, Miranda-Scippa A, Nery-Fernandes F, et al. The impact of comorbid posttraumatic stress disorder on bipolar disorder patients. J Affect Disord. 2010;123:71-76.

    Google Scholar 

  67. Goldberg JF, Garno JL. Development of posttraumatic stress disorder in adult bipolar patients with histories of severe childhood abuse. J Psychiatr Res. 2005;39:595-601.

    Google Scholar 

  68. Read J. Breaking the silence: learning why, when and how to ask about trauma, and how to respond to disclosure. In Larkin W, Morrisons A, eds. Trauma and Psychosis. London, UK: Brunner-Routledge; 2006:195-221.

    Google Scholar 

  69. Frueh BC, Grubaugh AL, Cusack KJ, Kimble MO, Elhai JD, Knapp RG. Exposure-based cognitive-behavioral treatment of PTSD in adults with schizophrenia or schizoaffective disorder: a pilot study. J Anxiety Disord. 2009;23:665-675.

    Google Scholar 

  70. Van den Berg DPG, van der Gaag M. Treating trauma in psychosis with EMDR: a pilot study. J Behav Ther Exp Psychiatry. 2012;43:664-671.

    Google Scholar 

  71. Mueser KT, Rosenberg SD, Xie H, et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. J Consult Clin Psychol. 2008;76:259-71.

    Google Scholar 

  72. Lambert TJ. Disease management: multidimensional approaches to incomplete recovery in psychosis. In Elkis H, Meltzer HY, eds. Therapy-Resistant Schizophrenia. Basel, Switzerland: Karger; 2010:87-113.

    Google Scholar 

  73. Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med. 2011;123:153-162.

    Google Scholar 

  74. McIntyre RS. Asenapine: a review of acute and extension phase data in bipolar disorder. NS Neurosci Ther. 2011;17:645-648.

    Google Scholar 

  75. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519-526.

    Google Scholar 

  76. Loebel A, Cucchiaro J, Ogasa M, et al. Efficacy of lurasidone: summary of results from the clinical development program. Poster presented at: New Research Approaches to Mental Health Interventions (NCDEU) meeting; June 14-17, 2010; Boca Raton, FL.

    Google Scholar 

  77. Cucchiaro J, Silva R, Ogasa M, et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebocontrolled PEARL 2 trial. Schizophr Res. 2010;117:493.

    Google Scholar 

  78. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care. 1999;37(4 suppl Lilly):AS81-AS86.

    Google Scholar 

  79. Gutierrez-Casares JR, Canas F, Rodriguez-Morales A, Hidalgo-Borrajo R, Alonso-Escolano D. Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. CNS Spectr. 2010;15:327-337.

    Google Scholar 

  80. Haddad P, Lambert T, Lauriello J, eds. Antipsychotic Long-Acting Injections. New York, NY: Oxford University Press; 2011.

    Google Scholar 

  81. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35:2072-2082.

    Google Scholar 

  82. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13:635-647.

    Google Scholar 

  83. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116:107-117.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany

    Martin Lambert & Dieter Naber

Authors
  1. Martin Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dieter Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Lambert .

Editor information

Editors and Affiliations

  1. Martinistr. 52, Hamburg, 20246, Hamburg, Germany

    Martin Lambert

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare, a part of Springer Science+Business Media

About this chapter

Cite this chapter

Lambert, M., Naber, D. (2013). Current Topics. In: Lambert, M. (eds) Current Schizophrenia. Springer Healthcare, Heidelberg. https://doi.org/10.1007/978-1-908517-68-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-68-5_2

  • Published:

  • Publisher Name: Springer Healthcare, Heidelberg

  • Print ISBN: 978-1-908517-46-3

  • Online ISBN: 978-1-908517-68-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation